Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
08:00am, Thursday, 19'th Sep 2024
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388
04:05pm, Thursday, 12'th Sep 2024
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothe
Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:00am, Thursday, 05'th Sep 2024
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
05:12pm, Monday, 19'th Aug 2024
Appointment adds biotech veteran with over two decades of business development, strategy, and operational experience to Cidara's management team Appointment adds biotech veteran with over two decades
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
04:29pm, Tuesday, 13'th Aug 2024
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (D
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01:05pm, Wednesday, 03'rd Jul 2024
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothe
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
08:00am, Thursday, 30'th May 2024
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:20pm, Wednesday, 15'th May 2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DF
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
04:01pm, Wednesday, 15'th May 2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
NEW YORK, May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutic
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
06:01pm, Friday, 26'th Apr 2024
Cidara Therapeutics, Inc. passed rezafungin rights to Mundipharma allowing reallocation of resources to the oncology Cloudbreak platform. Following a considerable private placement and re-acquisition
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
08:00am, Friday, 26'th Apr 2024
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NAS
Cidara Therapeutics shares surge 30% after reacquiring flu treatment
07:19pm, Wednesday, 24'th Apr 2024
Shares of Cidara Therapeutics CDTX, +19.90% rose sharply after the company announced a reshuffling of its portfolio of drug candidates.
